CA-QAD-INC
14.5.2024 09:01:37 CEST | Business Wire | Press release
QAD Inc., a leading provider of next-generation manufacturing and supply chain solutions in the cloud, has opened registration for its new EMEA customer conference, QAD Transform Europe, a complimentary two-day event happening 24-25 September in Brussels, Belgium.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240514413631/en/
Customers, sponsors and other members of the QAD community will join manufacturing and supply chain leaders from across Europe for two days of networking, education and technology innovation. Attendees will hear from industry experts and peers about the state of manufacturing and supply chains, what the future may bring and how to stay adaptive.
“QAD Transform Europe is our fresh take on regional events designed for and tailored to the customer,” said QAD Chief Product and Marketing Officer Carter Lloyds. “We recognize that manufacturing and supply chain leaders continue to face uncertainty and change in their business. The only way to survive and thrive is to transform. We look forward to sharing our roadmap for transformation at the event.”
The agenda for QAD Transform Europe will address the fundamental reasons businesses need to transform to survive, and help map the journey to get there. QAD leaders will outline the company’s plans for how to navigate today and tomorrow and QAD customers will share their success stories.
Agenda Highlights:
- Introducing the Industrial Transformation Platform — QAD’s roadmap to help companies transform into an Adaptive Enterprise by QAD CEO Anton Chilton
- Panel discussion with industry leaders on the transformation imperative
- Effective change management across your organization
- Uncovering root causes — not symptoms — of supply chain disruption
- Keynote address on QAD’s technology strategy and the benefits of the Cloud with QAD CTO Tony Winter
- Keynote address on Artificial Intelligence with Jeroen Baert, Computer Scientist, Comedian, Geek
- Leveraging pragmatic AI in supply chains
- Aligning ESG and sustainability with commercial objectives
- QAD new flagship ERP release — ERP O³
- Product updates on QAD Redzone Connected Workforce, QAD GTTE, QAD SRM, QAD DSCP and QAD Process Intelligence
- The new QAD roadmap for the food and beverage industry
- Breakout sessions and QAD Sponsor Expo
On Day 1, QAD executives and guest speakers will share an update on QAD today and the Industrial Transformation Platform, a panel discussion with industry experts on the need for transformation, the QAD roadmap and customer success stories. A networking reception and dinner with fellow manufacturing and supply chain leaders will follow.
On Day 2, guest keynotes will present on Effective Change Management, followed by a presentation on the state of Artificial Intelligence. More great breakout sessions and a networking lunch with QAD will follow as well as a Sponsor Expo to see QAD solutions in action.
The full agenda can be accessed here. For the latest updates on QAD Transform Europe, follow us on social media and engage using #QADTransform.
Event Details
What: QAD Transform Europe Customer Conference
When: 24-25 September, 2024
Where: Cardo Brussels Hotel | Brussels, Belgium
Registration: To register to attend QAD Transform Europe, click here.
About QAD – Enabling Adaptive Enterprises
QAD Inc. is a leading provider of next-generation manufacturing and supply chain solutions in the cloud. To succeed in a turbulent world, facing disruptions in supply and fluctuations in demand, manufacturers and supply chains must rapidly respond to change and seamlessly optimize agility, efficiency, and resilience for effective customer service. QAD delivers Adaptive Applications to enable these Adaptive Enterprises.
Founded in Santa Barbara, California, QAD has customers in 84 countries around the world. Thousands of companies have deployed QAD enterprise solutions including enterprise resource planning (ERP), digital commerce (DC), supplier relationship management (SRM), digital supply chain planning (DSCP), global trade and transportation execution (GTTE), enterprise quality management system (EQMS), connected workforce and process intelligence. To learn more, visit www.qad.com or call +1 805-566-6100. Find us on LinkedIn, X, Facebook and Instagram.
“QAD” is a registered trademark of QAD. All other products or company names herein may be trademarks of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240514413631/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom